CORRESP

KEZAR LIFE SCIENCES, INC.

4000 Shoreline Court, Suite 300

South San Francisco, CA 94080

July 9, 2019

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Donald Field

 

Re:

Kezar Life Sciences, Inc.

    

Registration Statement on Form S-3

    

File No. 333-232542

 

    

Acceleration Request

  Requested Date:

Thursday, July 11, 2019

  Requested Time:

4:00 P.M. Eastern Daylight Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-232542) (theRegistration Statement”) to become effective on Thursday, July 11, 2019, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP, counsel to the Registrant, confirming this request. The Registrant hereby authorizes each of Laura Berezin or Jaime Chase of Cooley LLP to make such request on its behalf.

[Signature page follows]


Very truly yours,
Kezar Life Sciences, Inc.
By:  

/s/ Marc Belsky

  Marc Belsky
  Chief Financial Officer

 

cc:

John Fowler, Kezar Life Sciences, Inc.

    

Laura Berezin, Cooley LLP

    

Jaime Chase, Cooley LLP

    

Robert Phillips, Cooley LLP